

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-13 (Canceled).

Claim 14 (Currently Amended): A delivery vehicle suitable for local, non-systemic administration of a drug to a body and directly to tissue within a body cavity having been subjected to a surgical procedure, said vehicle comprising Pemirolast or an analog thereof in an amount effective to inhibit formation of post-operative adhesions upon local, non-systemic administration of said Pemirolast to said tissue, wherein the delivery vehicle is selected from the group consisting of microcapsules, microspheres, barriers, liposomes, ~~osmotic pumps~~, fibers, filaments, gels, foams and films, and wherein said delivery vehicle comprises a polymer selected from the group consisting of poloxamers, poly(orthoester)s, poly(vinyl alcohol)s, poly(anhydride)s, poly(methacrylate)s, poly(methacrylamide)s, anionic carbohydrate polymers, poly(hydroxybutyric acid)s, polyacetals, poly(L-lactide), poly(DL-lactide), poly(DL-lactide-co-glycolide)s, poly(L-lactide-co-glycolide)s, poly(e-caprolactone), polyglycolide, poly(p-dioxanone)s, poly(trimethylene carbonate), poly(alkylene diglycolate)s, poly(oxaester)s, poly(oxaamide)s and glyceride polymers, and

the Pemirolast or analog thereof is present in an amount of from about 0.01 milligram Pemirolast or analog thereof per kilogram of the body to about 3,000 milligram Pemirolast or analog thereof per kilogram of the body.

Claims 15-16 (Canceled).

Claim 17 (Previously Presented): The delivery vehicle of claim 14 wherein said liposome is selected from the group consisting of L-alpha-distearoyl phosphatidylcholine, phosphatidylcholine, dipalmitoylphosphatidylcholine and egg phosphatidylcholine.

Claim 18 (Previously Presented): The delivery vehicle of claim 14 wherein said vehicle comprises a crystalloid instillate selected from the group consisting of phosphate buffered saline, saline and lactated Ringer's solution.

Claim 19 (Previously Presented): The delivery vehicle of claim 14 wherein said vehicle comprises viscous instillate comprising a carrier selected from the group consisting of dextrans, cyclodextrans, hydrogels, carboxymethylcellulose, poly(saccharide)s, hyaluronic acids, crosslinked hyaluronic acids and chondroitin sulfates.

Claim 20 (Canceled).

Claim 21 (Previously Presented): The delivery vehicle of claim 19 wherein said barrier is selected from the group consisting of hyaluronic acids, cellulose derivatives, collagens, recombinant human collagen, polyethylene glycols, pluronics, chitin, chitosans, dextrans, glucoses, carbohydrates, gelatins, glycosaminoglycans, polyacrylamides, polyvinyl pyrrolidones, polyvinyl alcohols, polymethacrylics, alginates, starches and polypeptides.

Claim 22 (Previously Presented) The delivery vehicle of claim 14 additionally comprising a second therapeutic agent in an amount effective to provide the therapeutic effect intended by administration of said therapeutic agent.

Claim 23 (Original): The delivery vehicle of claim 22 wherein said therapeutic agent is selected from the group consisting of an anti-platelet, an anti-fibrotic, an

anti-inflammatory, an anti-proliferative and an agent that inhibits collagen synthesis.

Claim 24 (Original): The delivery vehicle of claim 14 wherein said vehicle provides for single dose administration of said Pemirolast or analog thereof.

Claims 25-27 (Canceled).

Claim 28 (Currently Amended): A composition suitable for local, non-systemic administration of a drug to a body and directly to tissue within a body cavity having been subjected to a surgical procedure, said composition comprising Pemirolast or an analog thereof in an amount effective to inhibit formation of post-operative adhesions upon local, non-systemic administration of said composition to said tissue, and a carrier suitable for local, non-systemic administration of said Pemirolast or analog thereof, wherein the delivery vehicle is selected from the group consisting of microcapsules, microspheres, barriers, liposomes, ~~osmotic pumps~~, fibers, filaments, gels, foams and films, and wherein said delivery vehicle comprises a polymer selected from the group consisting of poloxamers, poly(orthoester)s, poly(vinyl alcohol)s, poly(anhydride)s, poly(methacrylate)s, poly(methacrylamide)s, anionic carbohydrate polymers, poly(hydroxybutyric acid)s, polyacetals, poly(L-lactide), poly(DL-lactide), poly(DL-lactide-co-glycolide)s, poly(L-lactide-co-glycolide)s, poly( $\epsilon$ -caprolactone), polyglycolide, poly(p-dioxanone)s, poly(trimethylene carbonate), poly(alkylene diglycolate)s, poly(oxaester)s, poly(oxaamide)s and glyceride polymers, and the Pemirolast or analog thereof is present in an amount of from about 0.01 milligram Pemirolast or analog thereof per kilogram of the body to about 3,000 milligram Pemirolast or analog thereof per kilogram of the body.

Claims 29-30 (Canceled).

U.S. Serial No. 10/780,452

Response dated: August 31, 2011

Supplemental Response to Office Action dated: April 11, 2011

Claim 31 (Original): The composition of claim 28 wherein said composition provides for single dose administration of said Pemirolast or analog thereof.

Claims 32-34 (Canceled).

Claim 35 (Previously Presented): The composition of claim 28 wherein said liposome is selected from the group consisting of L-alpha-distearoyl phosphatidylcholine, phosphatidylcholine, dipalmitoylphosphatidylcholine and egg phosphatidylcholine.

Claim 36 (Previously Presented): The composition of claim 28 wherein said vehicle comprises a crystalloid instillate selected from the group consisting of phosphate buffered saline, saline and lactated Ringer's solution.

Claim 37 (Previously Presented): The composition of claim 28 wherein said vehicle comprises viscous instillate comprising a carrier selected from the group consisting of dextrans, cyclodextrans, hydrogels, carboxymethylcellulose, poly(saccharide)s, hyaluronic acids, crosslinked hyaluronic acids and chondroitin sulfates.

Claim 38 (Canceled).

Claim 39 (Previously Presented): The composition of claim 28 wherein said barrier is selected from the group consisting of hyaluronic acids, cellulose derivatives, collagens, recombinant human collagen; polyethylene glycols, pluronics, chitin, chitosans, dextrans, glucoses, carbohydrates, gelatins, glycosaminoglycans, polyacrylamides, polyvinyl pyrrolidones, polyvinyl alcohols, polymethacrylics, alginates, starches and polypeptides.

U.S. Serial No. 10/780,452

Response dated: August 31, 2011

Supplemental Response to Office Action dated: April 11, 2011

Claim 40 (Previously Presented): The composition of claim 28 additionally comprising a second therapeutic agent in an amount effective to provide the therapeutic effect intended by administration of said therapeutic agent.

Claim 41 (Previously Presented): The composition of claim 40 wherein said therapeutic agent is selected from the group consisting of an anti-platelet, an anti-fibrotic, an anti-inflammatory, an anti-proliferative and an agent that inhibits collagen synthesis.